Introduction {#s0001}
============

In Norway, the nursing home (NH) sector comprising 42,000 beds provide care for both physically disabled and psychogeriatric patients. About 80% of NH patients are cognitively impaired and most have at least one significant neuropsychiatric symptom \[[@C1],[@C2]\]. A typical NH patient is an old (mean age, 86 years) and frail female with short life expectancy \[[@C3]\]. Because of multiple comorbidities, they use around eight drugs on a regular basis \[[@C1],[@C4],[@C5]\] and have thus an increased risk of drug--drug interactions \[[@C4]\] and adverse drug reactions \[[@C6]\]. Frailty, cognitive impairment \[[@C3]\] and age-related changes in pharmacokinetics and pharmacodynamics add further to these risks \[[@C7]\].

A drug-related problem (DRP) is 'an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes' \[[@C8]\]. Previous Norwegian studies using different tools for identifying drug--drug interactions \[[@C9]\] and potentially inappropriate prescriptions for the elderly \[[@C10],[@C11]\] have reported that NH patients are frequently exposed to DRPs \[[@C1],[@C12],[@C13]\].

In the NH setting, medication reviews (MRs) are recommended for improving the quality and the follow-up of the drug therapy by substantiating needs for continued use or for better balancing risks with potential benefits \[[@C14],[@C15]\]. However, although MRs may identify and resolve DRPs, there is a lack of evidence about their effects on 'hard' patient outcomes such as adverse drug events, hospital admissions or death \[[@C15]\]. MRs involving collaboration between physicians, pharmacists and nurses have been used in NH settings in several countries \[[@C1],[@C13],[@C16]\] and such collaboration is recommended in the Norwegian national guideline \[[@C14]\].

The aims of this study were to describe the DRPs identified at multidisciplinary MRs and the interventions that were carried out to resolve them, as well as changes in drug use that followed the MRs. We explored some predictors for the observed changes.

Methods {#s0002}
=======

Patients {#s0003}
--------

Of the 51 NHs in Oslo with long-term care patients (*n* = 4020), 41 accepted to participate in a MR project involving one or more units in their institutions. The project took place between November 2011 and February 2014. Except for those terminally ill, all patients (next of kin for patients with dementia) at the participating units were asked to participate in the MR project (*n* = 2625 patients). Eighteen refused and 142 scheduled MRs were not performed because the patient either died (*n* = 32), became terminally ill (*n* = 33), moved to another institution (*n* = 18), or for some other logistical reasons (*n* = 59). Therefore, a total of 2465 patients (on average 60 patients/NH, range 19--136) had their medication use reviewed by a multidisciplinary team.

Medication reviews {#s0004}
------------------

The MRs were conducted as a structured evaluation of each patient's drug use by the NH physician and a registered nurse employed at the unit in collaboration with an externally hired clinical pharmacist. Training sessions were held for the involved physicians, nurses and pharmacists before project start.

From the patient's anonymized medication lists, the pharmacist identified potential DRPs using explicit criteria for pharmacological inappropriateness listed in the STOPP/START criteria \[[@C10]\] and the Norwegian general practice (NORGEP) criteria for assessing potentially inappropriate prescribing to older persons \[[@C11]\] together with the drug--drug interaction database DRUID \[[@C9]\]. At the MR meeting, the physician provided supplementary clinical information from the patient's medical record. The medication and the possible DRPs were discussed aiming at consensus on measures to improve the patient's medication use. In case of disagreement, the physician held the final decision. DRPs and interventions on the drug use were classified according to a consensus-based classification system \[[@C8]\] (see [Box 1](#box1){ref-type="boxed-text"}). Medication lists for about eight patients were reviewed at each meeting that lasted about two hours. The interventions accepted by the patient (next of kin for patients with dementia) were thereafter implemented.

Classification of DRPs \[[@C8]\]: Drug choice problem, with subcategories: 1(a) need for additional drug, 1(b) unnecessary drug, 1(c) inappropriate drug choice;Dosing problem, with subcategories: 2(a) too high, 2(b) too low, 2(c) suboptimal dosing scheme, 2(d) suboptimal formulation;Adverse drug reactions;Interactions;Inappropriate drug use, with subcategories 5(a) administered by health personnel, 5(b) administered by patient;Other, with subcategories: 6(a) monitoring of drug use required, 6(b) unclear documentation, 6(c) not classified.

**Classification of interventions to resolve DRPs**: Stop the drugDrug switchStart new drugAdjust the drug doseMonitor the drug useOther measures

Data retrieval for the present study {#s0005}
------------------------------------

The following variables were recorded in our data set: NH identification number, patient's age and gender, patient's drugs in use before and after the MR (drug name, regular or prn use), DRPs (category linked to the drug involved) and interventions implemented (category linked to the drug involved).

Drugs were categorized according to the Anatomical Therapeutic Chemical (ATC) classification system \[[@C19]\]. Drug items without ATC codes (e.g. nutritional supplements, multivitamins) were not included. A drug--drug interaction was recorded as only one DRP.

Statistics {#s0006}
----------

Descriptive statistical analyses were performed using IBM SPSS Statistics v.24 (IBM Corp., Armonk, NY). We explored whether DRPs or the change in the number of drugs after the MR were associated with the patients' age or gender using a Poisson regression model with NH random effects (RE) in Stata SE 14 (Stata Corp LP, College Station, TX). The model was fitted to the individual data of each patient with MR (*n* = 2465), grouped at the level of the NHs (*n* = 41) and further adjusted for drug counts at baseline. Model estimates in terms of incidence rate ratios (IRR) and their 95% confidence intervals for numbers of DRPs and drugs after MR were calculated for both genders and different age groups (≥90 years as reference group). The significance level was set at α = 0.05.

Ethics {#s0007}
------

After reviewing the research study protocol, the Regional Committee in Medical Research Ethics in South-East Norway (reference no. 2015/786) and the Norwegian Centre for Research Data (reference no. 2015/43659) concluded that their approvals were not needed.

Results {#s0008}
=======

The mean age of the 2465 patients was 85.9 years (range 36--108) and women were older than men (mean 86.9 and 82.8 years, respectively). Patients' baseline characteristics are presented in [Table 1](#TB1){ref-type="table"}.

###### 

Baseline characteristics of the long-term care patients participating in the medication review project.

  Variables                   All patients    Age \<80 years   Age 80--89 years   Age ≥90 years
  --------------------------- --------------- ---------------- ------------------ ---------------
  Patients with MR, *n* (%)   2465 (100)      463 (18.8)       1023 (41.5)        979 (39.7)
  Gender, *n* (%)                                                                 
  Female                      1828 (74.2)     274 (59.2)       752 (73.5)         802 (81.9)
  Male                        630 (25.6)      188 (40.6)       267 (26.1)         175 (17.9)
  Number of drugs, *n* (%)                                                        
  Regular drugs               16,634 (69.3)   3324 (68.3)      6960 (70.7)        6350 (68.3)
  Prn drugs                   7369 (30.7)     1540 (31.7)      2881 (29.3)        2948 (31.7)
  Total drugs                 24,003 (100)    4864 (100)       9841 (100)         9298 (100)
  Mean drugs/patient(±SD)                                                         
  Regular drugs               6.8 ± 3.3       7.2 ± 3.6        6.8 ± 3.3          6.5 ± 3.1
  Prn drugs                   3.0 ± 2.1       3.3 ± 2.3        2.8 ± 2.0          3.0 ± 2.2
  Total drugs                 9.8 ± 4.4       10.5 ± 4.7       9.6 ± 4.3          9.5 ± 4.3

Missing gender data (7 patients).

The mean numbers of drugs by gender were similar: 6.8 for regular drugs and 3.0 for prn drugs.

In total, the MR identified 6158 DRPs, an average of 2.6 DRPs/patient (range 0--14), 2.0 for regular and 0.6 for prn drugs. In total, 17.3% of the patients had no DRP at the MR. The 82.7% of the patients with DRPs had an average of 3.0 DRPs/patient, 2.3 for regular and 0.7 for prn drugs. Female gender (IRR with 95% CI: 1.11 \[1.04--1.17\]) was associated with an increased risk of DRPs, but not age.

The DRPs and the drugs most commonly related to them are listed in [Table 2](#TB2){ref-type="table"}. Overall, 6409 drugs were involved in the DRPs (75.2% regular drugs and 24.8% prn drugs). Drugs used prn were most commonly involved in the DRP categories unnecessary drug use (43%), inappropriate drug choice (25%) and excess dosing (11%) and they most commonly consisted of opioids (20.7%), anxiolytics (15.6%) and hypnotics/sedatives (11.8%).

###### 

Categories of drug-related problems and the three drugs (therapeutic groups) most commonly involved in the problem listed.

  Drug-related problems (*n* = 6158)   The three drugs most commonly involved in the drug-related problems listed                                                                                                                                                 
  ------------------------------------ ---------------------------------------------------------------------------- -------------------------------------------------------- ----- -------------------------------------------- ----- --------------------------- -----
  Unnecessary drug                     2680 (43.5)                                                                  Hypnotics/sedatives                                      296   Opioids[^b^](#TF4){ref-type="table-fn"}      249   Anxiolytics                 213
  Excess dosing                        770 (12.5)                                                                   Paracetamol                                              108   Antacid drugs                                103   Hypnotics/sedatives         92
  Monitoring of drug use required      680 (11.0)                                                                   Antidepressants                                          103   Antidementia drugs                           48    Renin--angiotensin system   46
  Inappropriate drug choice            503 (8.2)                                                                    Opioids                                                  80    Anxiolytics                                  56    Hypnotics/sedatives         43
  Need for additional drug             453 (7.4)                                                                    Anti-anaemia drugs[^a^](#TF3){ref-type="table-fn"}       130   B-complex vitamins                           62    Paracetamol                 43
  Adverse drug reaction                287 (4.7)                                                                    Hypnotics/sedatives                                      37    Anxiolytics                                  32    Antipsychotics              28
  Drug--drug interactions              271 (4.4)                                                                    Antidepressants                                          124   Antithrombotic agents                        66    Opioids                     50
  Under-dosing                         169 (2.7)                                                                    Paracetamol                                              27    Opioids                                      26    Thyroid therapy             23
  Suboptimal dosing/formulation        141 (2.4)                                                                    Beta-blockers                                            21    Paracetamol                                  18    Hypnotics/sedatives         6
  Other                                127 (2.0)                                                                    Anti-thrombotic agents[^d^](#TF6){ref-type="table-fn"}   17    Opioids                                      7     Anxiolytics                 7
  Inappropriate drug use               77 (1.2)                                                                     Paracetamol                                              12    COPD drugs[^c^](#TF5){ref-type="table-fn"}   9     Opioids                     4

iron supplements, B~12~ vitamin and folate.

ATC-N02A comprising weak opioids (codeine, tramadol) and strong opioids.

Chronic obstructive pulmonary disease drugs comprising adrenergic/anti-cholinergic drugs (systemic or inhalation use) and glucocorticoids (inhalation use).

ATC-B01A (mainly warfarin, acetylsalicylic acid and heparin).

The 6158 DRPs led to 6283 interventions to change the drug therapy, including 125 drug--drug interactions that led to changes in the use of both drugs ([Table 3](#TB3){ref-type="table"}). Of the 2662 discontinued drugs, 47.6% were drugs for prn use, most commonly opioids (20.6%), anxiolytics (14.5%) and hypnotics/sedatives (12.9%). Dosage adjustments and needs for closer monitoring the drug use involved almost exclusively drugs for regular use (96%). The proposed changes in drug therapy were implemented, except for 31 that were declined by the patient (next of kin for patients with dementia).

###### 

Interventions to resolve drug-related problems (DRPs) and the three drugs (therapeutic groups) most commonly involved in changes to the drug therapy regimens.

  **Interventions to resolve DRPs** (*n* = 6283)   The three drugs most commonly involved in the interventions listed                                                                                                                                                                             
  ------------------------------------------------ -------------------------------------------------------------------- ----------------------------------------------------- ----- ------------------------------------------------------- ----- ----------------------------------------------- -----
  Stop drug                                        2662 (42.4)                                                          Opioids[^a^](#TF7){ref-type="table-fn"}               293   Hypnotics/sedatives                                     242   Anxiolytics                                     217
  Monitor drug use                                 1455 (22.7)                                                          Antidepressants                                       182   Antithrombotic agents[^b^](#TF8){ref-type="table-fn"}   112   Hypnotics/sedatives                             84
  Dose adjustment                                  1141 (17.8)                                                          Hypnotics/sedatives                                   131   Paracetamol                                             128   Antacid drugs[^c^](#TF9){ref-type="table-fn"}   112
  Drug switch                                      438 (6.8)                                                            Opioids                                               68    Hypnotics/sedatives                                     41    Diuretics                                       32
  Start new drug                                   436 (6.8)                                                            Anti-anaemia drugs[^d^](#TF10){ref-type="table-fn"}   124   B-complex vitamins                                      62    Paracetamol                                     41
  Other                                            151 (2.4)                                                            Paracetamol                                           17    Beta-blockers                                           13    Hypnotics/sedatives                             8

ATC-N02A comprising weak opioids (codeine, tramadol) and strong opioids.

ATC-B01A (mainly warfarin, acetylsalicylic acid and heparin).

Mainly proton pump inhibitors.

Iron supplements, B~12~ vitamin and folate.

After the MR, the total number of drugs used by all patients went down by 9.3% (from 24,003 to 21,777 drugs; *p* \< .01). The mean number of drugs per patient went down from 9.8 to 8.9 (*p* \< .001) and the decrease was significant (*p* \< .001) for both regular (from 6.8 to 6.3) and prn drugs (from 3.0 to 2.6). For the 82.7% of the patients who had any DRPs, the average decrease in the number of drugs was 1.1 (0.5 for regular and 0.6 for prn drugs). No associations were found between the change in the number of drugs (regular or prn) and the patients' age or gender. The changes in the drug use following the MRs are presented for regular and prn drugs in [Tables 4](#TB4){ref-type="table"} and [5](#TB5){ref-type="table"}, respectively. Individual drugs for regular use, which were most commonly discontinued after the MR, were zopiclone (from 23.4% to 20.4%, *p* \< .01) and furosemide (from 14.7% to 11.8%, *p* \< .001). The prn drugs most often discontinued were oxazepam (from 37.5% to 32.8%, *p* \< .001), zopiclone (from 15.6% to 12.9%, *p* \< .01), metoclopramide (from 12.5% to 9%, *p* \< .001), and clomethiazole (from 7.1% to 4.8%, *p* \< .001).

###### 

The proportion of patients using regular drugs before and after the medication review and reductions in drug use after the medication review.

                           All patients, *n* = 2465 % of patients using the drug            
  ------------------------ ------------------------------------------------------- -------- ------------------
  Laxatives                82.0                                                    81.6     0.4
  Antithrombotic agents    46.2                                                    43.5     2.7 (--1.0--5.5)
  Paracetamol              44.5                                                    43.7     0.8
  Antidepressants          37.2                                                    33.3     3.9 (1.2--6.6)
  Opioids                  34.3                                                    33.1     1.2
  Hypnotics/sedatives      32.6                                                    28.9     3.7 (1.1--6.3)
  Diuretics                32.0                                                    27.3     4.7 (2.2--7.2)
  Anti-anaemia drugs       27.1                                                    26.2     0.9
  Beta-blockers            24.9                                                    23.9     1.0
  Anxiolytics              21.4                                                    20.2     1.2
  Antacid drugs            21.0                                                    18.9     2.1 (--0.1--4.3)
  Osteoporosis drugs       20.3                                                    19.5     0.8
  Thyroid therapy          20.2                                                    20.2     --
  COPD drugs               18.8                                                    17.4     1.4
  Antipsychotics           18.3                                                    16.5     1.8 (--0.3--3.9)
  Drugs for glaucoma       15.6                                                    15.4     0.2
  Antiepileptic drugs      12.4                                                    12.4     --
  Drugs used in diabetes   11.9                                                    11.4     0.5
  Digitalis and nitrates   11.9                                                    10.8     1.1
  Antidementia drugs       11.6                                                    10.5     1.1
  Antibiotics              9.8                                                     9.1      0.7
  Calcium blockers         8.6                                                     7.5      1.1
  Antihistamines           6.4                                                     5.0      1.4
  Lipid modifying agents   6.0                                                     5.1      0.9
  Oral corticosteroids     6.2                                                     6.0      0.2
  Anti-Parkinson drugs     5.4                                                     5.2      0.2
  Others                   86.5                                                    77.7     8.8 (6.4--11.2)
  Total *n* of drugs       16,634                                                  15,563   6.4 (2.2--4.4)

The 95% confidence interval is shown only if significant.

###### 

The proportion of patients using pro re nata drugs before and after the medication review and reductions in drug use after the medication review.

                           **All patients, *n* = 2465 % of patients using the drug**          
  ------------------------ ----------------------------------------------------------- ------ ------------------
  Paracetamol              49.0                                                        48.0   1.0
  Anxiolytics              48.1                                                        41.0   7.1 (4.3--9.9)
  Opioids                  38.9                                                        27.7   11.2 (8.6--13.8)
  Laxatives                29.1                                                        26.3   2.8 (0.3--5.3)
  Hypnotics/sedatives      24.9                                                        19.1   5.8 (3.5--8.1)
  Expectorants             12.9                                                        10.2   2.7 (0.9--4.5)
  Nitrates                 12.7                                                        11.8   0.9
  Metoclopramide           12.5                                                        9.0    3.5 (1.8--5.2)
  NSAIDs                   6.8                                                         3.9    2.9 (1.6--4.2)
  Diuretics                5.7                                                         5.1    0.6
  Drugs used in diabetes   5.2                                                         5.0    0.2
  Antipsychotics           4.9                                                         3.4    1.5 (0.4--2.6)
  Others                   48.0                                                        42.2   5.8 (1.7--9.9)
  Total *n* of drugs       7369                                                        6214   15.3 (6.6--10.0)

^a^The 95% confidence interval is shown only if significant.

Discussion {#s0009}
==========

To our knowledge, this is the first study to report the effect of multidisciplinary MRs at NHs in terms of DRPs and drug use changes related to both regular and prn drugs.

We found on average 2.6 DRPs/patient (3.0 for patients with DRPs) and that regular drugs contributed to 77% of all DRPs. Psychotropic drugs and opioids were most commonly involved in all types of DRPs and the subsequent interventions. The use of all therapeutic drug groups went down after MR, except for thyroid therapy. In the 82.7% of the patients with DRPs, the number of drugs was reduced with on average 1.1 drugs; most discontinued medications comprised opioids and psychotropic drugs, which should be used with caution in frail elderly.

Our study has some limitations that warrant consideration. We have analysed data from a pragmatic project without random patient selection or a control group for comparison. However, we consider the validity of the results to be reasonable high because 82% of all NHs included 61% of all long-term care patients in the municipality, and because terminal illness was the only exclusion criterion. Furthermore, the patients' age and sex distribution correspond well with that of the total NH population in the city and country \[[@C4],[@C12],[@C13],[@C20]\]. Similar MR procedures at the various sites were ensured through training of the MR teams, standardized tools and classification systems \[[@C8]\] and because each pharmacist participated in several hundred MRs. The use of the NORGEP criteria \[[@C11]\] may be questioned because they were not developed in particular for nursing home settings and because more recent criteria tailored for the nursing home setting, the NORGEP-NH criteria \[[@C23]\] are now available. However, the NORGEP-NH criteria had not been published when this study started and it was the STOPP-START and NORGEP criteria that were included in in the national guideline for MRs in nursing homes \[[@C14]\].

Although direct comparison with other studies is challenged by differences in MR procedures or drugs targeted, the distribution of the DRPs is comparable to other studies \[[@C1],[@C13],[@C16]\], with problems most frequently associated with unnecessary drug use, excess dosing or inadequate monitoring/follow-up of the drug therapy. The lower prevalence of DRPs as compared to other Norwegian studies reporting 2.5--3.5 DRPs/patient \[[@C1],[@C12],[@C13]\], might be related to more staffing with full-time rather than part-time physicians in Oslo and an increased focus in recent years on safer prescribing practice for the elderly. The average number of drug used per patient before the MR compares well or is slightly lower than in other studies reporting 6.1--9.8 regular \[[@C1],[@C4],[@C5],[@C13],[@C16],[@C20],[@C24],[@C25]\] and 2.8--3.8 prn drugs \[[@C4],[@C20]\]. The high drug utilization at NHs may also partly reflect that the drug regiments are based on guidelines developed for younger patients with less comorbidity and the lack of consensus on best practice for pharmacotherapy in the oldest old.

The higher use of opioids in our population as compared with findings in a previous Norwegian study \[[@C22]\] may be related to less use of NSAIDs and increased use for chronic pain. In NH patients with dementia, chronic pain is commonly communicated in terms of neuropsychiatric symptoms \[[@C2]\] and treatment of pain can reduce both agitation and other neuropsychiatric symptoms \[[@C26]\]. This may therefore also explain the more use of analgesics in our study.

Compared to other studies, we found a slightly higher use of hypnotics/sedatives \[[@C20],[@C21]\], but less use of antidepressants \[[@C13],[@C20],[@C21]\] and antipsychotics \[[@C20],[@C21]\] and a comparable use of anxiolytics \[[@C20],[@C21]\]. Although reduced, their utilization was still high after the MR, possibly reflecting the patients' need for continued treatment or reluctance among physicians and nursing staff to discontinue the drugs \[[@C27]\]. Studies of withdrawing long-term use of antipsychotics \[[@C28]\] or anti-depressants \[[@C29]\] in Norwegian NHs have shown that in most cases, discontinuation does not result in more NPS or relapse of depression. We do not know of any studies on discontinuing anxiolytics in NH residents. However, based on their questionable therapeutic long-term effects on anxiety symptoms \[[@C30]\], we consider that these drugs probably are still overused in frail NH patients who are at particular risk of falls and fractures \[[@C6]\].

Based on the results of this study, we support that MRs should be part of the regular clinical follow up of NH residents \[[@C14]\].

Conclusions {#s0010}
===========

The MR resulted in overall less drug use, most pronounced for psychotropic drugs and opioids, and in a closer follow-up to optimise the potential benefits of the drug use. Future research on MRs should include patient-related clinical outcomes.
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